Osterweis Capital Management Inc. Takes $5.82 Million Position in Glaukos Corporation $GKOS

Key Points

• Osterweis Capital Management Inc. acquired 59,133 shares of Glaukos Corporation, valued at approximately $5.82 million, representing 0.10% ownership as per their latest SEC filing.
• Institutional investors and hedge funds own 99.04% of Glaukos, with multiple firms recently increasing their stakes significantly during Q1.
• Glaukos reported a quarterly revenue of $124.12 million, exceeding analyst estimates and showing a year-over-year revenue increase of 29.7% despite posting a loss of ($0.24) earnings per share.

Osterweis Capital Management Inc. acquired a new stake in Glaukos Corporation (NYSE:GKOS - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 59,133 shares of the medical instruments supplier's stock, valued at approximately $5,820,000. Osterweis Capital Management Inc. owned about 0.10% of Glaukos as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of GKOS. Wellington Management Group LLP grew its position in shares of Glaukos by 6.1% during the 1st quarter. Wellington Management Group LLP now owns 2,290,790 shares of the medical instruments supplier's stock worth $225,460,000 after buying an additional 131,251 shares in the last quarter. Primecap Management Co. CA boosted its holdings in Glaukos by 0.3% in the first quarter. Primecap Management Co. CA now owns 1,218,475 shares of the medical instruments supplier's stock worth $119,922,000 after acquiring an additional 4,150 shares in the last quarter. Westfield Capital Management Co. LP boosted its holdings in Glaukos by 34.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier's stock worth $106,705,000 after acquiring an additional 277,033 shares in the last quarter. Gilder Gagnon Howe & Co. LLC boosted its holdings in Glaukos by 25.3% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier's stock worth $123,742,000 after acquiring an additional 166,677 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Glaukos by 7.4% in the fourth quarter. Northern Trust Corp now owns 578,673 shares of the medical instruments supplier's stock worth $86,766,000 after acquiring an additional 40,052 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Stock Performance

GKOS stock traded down $0.6790 during trading on Monday, hitting $93.4710. 127,031 shares of the company traded hands, compared to its average volume of 947,558. The stock's 50-day simple moving average is $96.26 and its 200 day simple moving average is $100.70. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The company has a market cap of $5.36 billion, a PE ratio of -56.67 and a beta of 0.78. Glaukos Corporation has a 1 year low of $77.10 and a 1 year high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The company had revenue of $124.12 million during the quarter, compared to analysts' expectations of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.Glaukos's quarterly revenue was up 29.7% on a year-over-year basis. During the same period last year, the business earned ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. On average, equities analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on GKOS shares. Wells Fargo & Company raised their price target on Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Mizuho set a $130.00 price target on Glaukos in a report on Thursday, July 31st. Zacks Research downgraded Glaukos from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. UBS Group raised their price target on Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Finally, Morgan Stanley lowered their price target on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $127.42.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.